视觉功能与阿尔茨海默病中的生物标志物变化有关
Ashar Memon1, Jasmine A Moore2,3,4, Chris Kang2,3
1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Journal of Alzheimer's disease : JAD
|April 26, 2024
概括
阿尔茨海默病的生物标志物,包括p-tau181/Aβ1-42比率和大脑体积,与视觉感知能力下降相关. 这些发现有助于评估疾病严重程度和建模认知进展.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 认知科学 认知科学
背景情况:
- 阿尔茨海默病 (AD) 生物标志物与一般认知有关,但它们对视觉感知功能的影响需要进一步研究.
- 视觉感知缺陷显著影响阿尔茨海默病患者的生活质量.
研究的目的:
- 研究各种流体和成像生物标志物之间的关联以及基于视觉的认知评估.
- 分析这些协会在阿尔茨海默病的全谱.
主要方法:
- 分析了来自1460名阿尔茨海默氏病神经成像倡议参与者的数据.
- 包括液体生物标记物,成像生物标记物,迷你精神状态检查 (MMSE),Trail Making Test (TMT) A和B,以及波士顿命名测试 (BNT).
- 应用本地估计的散射图平滑曲线和皮尔森相关系数来检查关联.
主要成果:
- 迷你心理状态检查 (MMSE) 证明了与大多数生物标志物的最强相关性.
- 步道制作试验B (TMT-B) 也显示了与几个生物标志物的显著相关性.
- 在p-tau181/Aβ1-42比率,海马体积和脑内皮层体积中,表现出最强烈的生物标志物关联.
结论:
- 多种生物标志物与整个阿尔茨海默氏病谱中的视觉处理缺陷有关.
- 这些生物标志物显示出评估疾病严重程度的潜力,并为AD视觉和认知进展的模型提供信息.
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


